You are here

Article Text

Article menu
Download PDFPDF
Novel treatment (new drug/intervention; established drug/procedure in new situation)
CASE REPORT
First US experience with Pipeline Flex with Shield Technology using aspirin as antiplatelet monotherapy
  1. Ricardo A Hanel1,
  2. Pedro Aguilar-Salinas1,
  3. Leonardo BC Brasiliense2,
  4. Eric Sauvageau1
  1. 1 Lyerly Neurosurgery, Baptist Neurological Institute, Jacksonville, Florida, USA
  2. 2 Division of Neurosurgery, University of Arizona, Tucson, Arizona, USA
  1. Correspondence to Dr Ricardo A Hanel, rhanel{at}lyerlyneuro.com

Summary

Flow diversion has revolutionised the treatment of intracranial aneurysms, and the Pipeline Embolization Device (PED) remains the only flow diverter (FD) approved in the USA. However, thromboembolic events remain an issue for FDs. Attempting to minimise these incidents, a newer PED has been developed with the use of covalent bonding of phosphorylcholine onto the Pipeline device that has been known as Shield Technology (PED Shield), which in vitro has demonstrated a significant reduction in material thrombogenicity. We report the first US experience of the PED Shield in the treatment of a ruptured fusiform aneurysm located in the right vertebral artery in an attempt to mitigate complications related to the use of dual-antiplatelet therapy and discuss our rationale for using the new FD, using aspirin only as the antiplatelet regimen.

  • Stroke
  • Interventional radiology
  • Neurosurgery

https://doi.org/10.1136/bcr-2017-219406

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors RAH and PA-S were responsible for study concept and design. PA-S contributed to the acquisition of the data. All the authors were responsible for analysis and interpretation of the data. PA-S and LBCB contributed to the drafting of the manuscript. RAH and ES contributed to the critical revision of the manuscript for important intellectual content. PA-S and LB were responsible for administrative, technical and material support. RAH and ES contributed to study supervision.

    • Competing interests RAH is a consultant for Covidien, Stryker, Codman, MicroVention and scientific advisory board for Medina Medical and shareholder for Blockade Medical. The other authors have no personal, financial or institutional interest in any of the drugs, materials or devices described in this article.

    • Patient consent Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.